Honasa Consumer Ltd shares declined 3.07% to ₹407 on the National Stock Exchange on Wednesday, reversing initial gains following the company's announcement of a majority stake acquisition in Fluence Pharma.
The market reaction suggests caution among investors regarding the execution of the deal, despite the strategic rationale for entering the nutraceuticals segment.
The acquisition involves a 58% controlling stake in Fluence Pharma, a science-backed nutraceuticals manufacturer, valuing the target at approximately ₹135 crore.
The acquisition involves a 58% controlling stake in Fluence Pharma, a science-backed nutraceuticals manufacturer, valuing the target at approximately ₹135 crore.
This move marks Honasa's formal expansion beyond its core personal care portfolio, aiming to capture growth in the health and wellness sector.
The Hindu Businessline and Livemint reported on the transaction details, noting the significant shift in the company's product strategy.
Honasa, best known for its Mamaearth brand, has been seeking avenues to diversify its revenue streams amid competitive pressures in the personal care market.